Skip to main content

Company

Melodiol Global Health Ltd

ASX:ME1

Melodiol Global Health Ltd (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. The company develops cannabis, hemp-derived and other plant-based therapeutic, nutraceutical and lifestyle products with wide consumer reach.

9 stories

Pharma & Biotech

Melodiol Global Health welcomes third straight quarter of revenue growth for Canadian subsidiary

By Proactive 09/10/2023

Melodial Global Health raising $1.4 million for sales initiatives and M&A

By Proactive 08/08/2023

Melodiol Global Health weighs asset sale with US-listed Panacea

By Proactive 02/08/2023

Melodiol Global Health's Mernova nears EU GMP certification for cannabis exports to Australia and Europe

By Proactive 26/07/2023

Melodiol Global Health optimistic about growth prospects thanks to subsidiary Health House’s strong H1 revenue

By Proactive 24/07/2023

Melodiol Global Health welcomes healthy revenue uptick to start 2023’s third quarter

By Proactive 19/07/2023

Melodiol Global Health posts “record-breaking” financials for quarter; group sales up 105%

By Proactive 13/07/2023

Melodiol Global Health's Canadian subsidiary Mernova posts record half-yearly revenues

By Proactive 10/07/2023

Melodial Global Health reports significant revenue growth from two key business units

By Proactive 03/07/2023